<DOC>
	<DOCNO>NCT00659659</DOCNO>
	<brief_summary>Evaluate safety tolerability MEDI-563 adult asthma effect MEDI-563 eosinophil count airway mucosal biopsy</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Effects MEDI-563 Adults With Asthma</brief_title>
	<detailed_description>Evaluate safety tolerability MEDI-563 adult atopic asthma ; evaluate effect MEDI-563 eosinophil count airway mucosal biopsy 28 day completion dose adult atopic asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female adult , 18 65 year age time randomization ; Written inform consent obtain subject prior beginning study procedure receipt study medication ; Previously document diagnosis asthma ≥ 1 year duration , base episodic symptom airflow obstruction ; postbronchodilator reversibility airflow obstruction ≥ 12 % ( USA subject achieve screening , proof ≥12 % reversibility within 1 year randomization acceptable ) proof positive response methacholine challenge screen prior approval MedImmune ( USA within 1 year randomization acceptable ) represent provoke concentration methacholine cause 20 % fall FEV1 ( PC20 ) &lt; 8 mg/ml [ American Thoracic Society ( ATS ) , 2000 ) ] ; exclusion alternative pulmonary diagnosis ( eg , cystic fibrosis , COPD ) ; Asthma symptom adequately control therapeutic regimen change last 4 week prior Study Day 0 , subject willing maintain therapeutic regimen dos time screen time first followup bronchoscopy airway mucosal biopsy ( Study Day 28 Cohort 1 ; Study Day 84 Cohort 2 ) ; Prebronchodilator FEV1/forced vital capacity ( FVC ) ratio ageadjusted normal limit define 2007 National Heart Lung Blood Institute Asthma guideline ( Appendix D ) postbronchodilator FEV1 ≥ 65 % screening ; Must ≥ 2.5 % eosinophils sputum ; Have hospitalization due asthma last year prior screening ; Women childbearing potential , unless surgically sterile least 1 year postmenopausal , must use 2 effective method avoid pregnancy Able complete followup period require protocol ; Willing forego form experimental treatment study procedure study 84day period last dose study drug ; Able provide spirometric reading meet ATS standard Participation previous MEDI563 clinical study ; Known history allergy adverse reaction component study drug formulation ; Lung disease asthma ( eg , COPD , cystic fibrosis , eosinophilic pneumonia ) ; Current use systemic inhaled immunosuppressive drug [ oral ( maximum dose 10 mg/day 20 mg every day ) inhale corticosteroid allow dose stable least 4 week prior study drug administration Study Day 0 ] . Current use βblocker ( eg , propranolol ) ; Acute illnesses evidence clinically significant active infection , fever ≥ 38.0ºC ( 100.5ºF ) screening time study drug administration Study Day 0 ; Receipt investigational drug therapy , intravenous immunoglobulin ( IVIG ) , monoclonal therapy ( eg , Xolair ) within 30 day within 5half life prior study drug administration Study Day 0 End Study/Study Termination ( Study Day 84 Cohort 1 Study Day 140 Cohort 2 ) ; Pregnancy ( woman childbearing potential must negative serum pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Breastfeeding lactating ; History alcohol drug abuse &lt; 1 year prior Study Day 0 ; History cancer , apart basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior Study Day 0 ; History previous episode active TB positive TB skin test without completion appropriate course treatment ; A history coagulation disorder would contraindicate mucosal biopsy ; History immunodeficiency infection HIV1 , HIV2 , hepatitis A , B , C virus ; History use tobacco product within 2 year baseline ( Study Day 0 ) history smoke ≥ 10 packyears ; Elective surgery plan time screen first followup bronchoscopy airway mucosal biopsy ( Study Day 28 Study Day 84 , applicable ) ; Evidence systemic disease respiratory disease ( asthma ) , history disease , find upon physical examination , screen laboratory test , chest Xray ( CXR ) , ECG , opinion investigator medical monitor , may compromise safety subject study confound analysis study result ; Any employee research site involve conduct study ; History lidocaine allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>